Phase 2 N=12 Dose-Escalation Safety and Pharmacokinetic Study of K305
Anesthesia
Primary: Cmax of Oxymetazoline — 1.45; 2.05 ng/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=268 A Study To Monitor Long-Term Treatment With PF-00547659
Crohn's Disease
Primary: Number of Participants With On-Treatment Adverse Events (AEs), AEs Led to Withdrawal, and Serious Adverse Events (SAEs) — 249; 53; 80 Participants
Phase 2 N=32 A Three Part Study of MGV354 in Ocular Hypertension or Glaucoma
Ocular Hypertension · Open-Angle Glaucoma
Primary: Part 3: Change in Diurnal IOP (Averaged Over 8 AM, 10 AM, Noon, 4 PM, and 8 PM) From Baseline to Day 8 — -0.6; -1.1 mmHg
Phase 2 N=46 Tandem Transplantation in Multiple Myeloma (MM) Patients With <12 Months of Prior Treatment
Multiple Myeloma
Primary: To Determine Whether, in Comparison to TT II, the Median EFS Can be Increased From 4.8 Years to 6.2 Years, Which Represents an Increase in Median EFS of Approximately 30%
Phase 2 N=75 Study of Modified FOLFIRINOX in Advanced Pancreatic Cancer
Metastatic Pancreatic Cancer · Pancreatic Cancer
Primary: Progression Free Survival — 54; 97 percentage of participants
Phase 2 N=11 Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
Relapsed or Refractory Multiple Myeloma
Primary: Maximally Tolerated Dose — 40 mg
Phase 2 N=48 Dose-Ranging Study of Intranasal Kovacaine Mist in Pediatric Subjects
Anesthesia
Primary: Number of Participants Who Completed the Study Dental Procedure Without Need for Rescue by Injection of Local Anesthetic. — 6; 7; 8; 5 Participants
Phase 2 N=87 Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease
Thyroid Associated Ophthalmopathies · Thyroid-Associated Ophthalmopathy
Primary: Responder Status at Week 24 — 9; 29; 36; 13 Participants — p=< 0.001
Phase 2 N=34 Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma
Hodgkin Lymphoma
Primary: Complete Response Rate — 31 Participants
Phase 2 N=32 Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Patients With Previously Untreated Extensive Stage Small-cell Lung Cancer
Extensive-Stage Small-Cell Lung Cancer
Primary: Number of Participants With Dose-limiting Toxicities — 0; 0; 0; 0 Participants
Phase 2 N=26 Bevacizumab and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
Liver Cancer
Primary: Median Progression-free Survival
Phase 2 N=50 Study of Sorafenib and Transarterial Chemoembolization (TACE) to Treat Hepatocellular Carcinoma
Hepatocellular Carcinoma · Hepatoma
Primary: Safety Will be Assessed by Grading Toxicities Reported at Intervals Throughout the Study. Higher Grade Toxicities Will be Assessed for Their Degree of Relatedness to the…
Phase 2 N=21 Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy
Brenner Tumor · Fallopian Tube Cancer · Ovarian Clear Cell Cystadenocarcinoma
Primary: Time to Progression — 4.07 months
Phase 2 N=43 Proof of Concept Study to Evaluate Safety and Efficacy of LME636 in the Treatment of Acute Anterior Uveitis
Acute Anterior Uveitis
Primary: Number of Responders at Day 15 — 14; 9 Participants
Phase 2 N=36 Study to Evaluate Pharmacokinetics Profile, Wearability, and Safety of 2 Progestin-Only Patches
Healthy
Primary: Levonorgestrel Pharmacokinetic Profile — 100; 83.3 % of subjects below 175 pg/mL